Blood tests for inflammation could help prevent heart attack, stroke

October 4, 2012
C-reactive protein, fibrinogen slightly improve risk modeling
The addition of C-reactive protein or fibrinogen offers a modest improvement to conventional cardiovascular risk modeling, according to a study published in the Oct. 4 issue of the New England Journal of Medicine.

(HealthDay)—Among people at high risk for cardiovascular disease, knowing their blood levels of two specific markers for inflammation might help prevent a heart attack or stroke, according to British investigators.

The two markers, C-reactive protein and fibrinogen, are produced in the liver in response to inflammation in the body. Whether measuring their levels can indeed stave off a cardiovascular event is a topic of scientific debate, the researchers said.

The new analysis suggests that although such testing would save some people from suffering a heart attack or stroke, the proportion of those benefited would not be large. The issue then becomes whether widespread testing is worthwhile.

"In a study of people without known cardiovascular disease, we estimated that under current treatment guidelines, one extra cardiovascular disease outcome would be prevented over a period of 10 years for approximately every 440 people in whom [C-reactive protein] levels were assessed or approximately every 490 people in whom fibrinogen levels were assessed," said lead researcher Dr. Emanuele Di Angelantonio, a lecturer in medical screening at the University of Cambridge.

The report was published in the Oct. 4 issue of the New England Journal of Medicine.

For the study, Di Angelantonio's team analyzed 52 studies that included more than 246,000 people who had no history of cardiovascular disease.

In this type of study, called a meta-analysis, researchers attempt to glean patterns from disparate sources to make a point not usually included in the original studies. The weaknesses of a meta-analysis are the inherent problems in the individual studies and the difficulty in fitting the data together.

In the new analysis, the group found that measuring C-reactive protein or fibrinogen, along with other standard tests such as blood pressure and cholesterol, in about 13,000 people identified as being at risk for cardiovascular disease could prevent a few strokes and heart attacks over time.

"If [C-reactive protein] or fibrinogen was assessed in people considered to be at intermediate risk after initial screening with the use of conventional risk factors alone—and if such measurement of a biomarker of inflammation were to be coupled with initiation of statin [therapy]—our data suggests [that such assessment] could help prevent approximately 30 additional cardiovascular events over the course of 10 years," Di Angelantonio said.

Dr. Gregg Fonarow, professor of cardiology at the University of California, Los Angeles, and a spokesman for the American Heart Association, said: "Many prior studies have demonstrated that blood tests for C-reactive protein and fibrinogen, when assessed in isolation, are predictive of subsequent cardiovascular events.

"However, the extent to which these tests offer incremental value beyond traditional-risk cardiovascular-risk models has not been well defined and is the subject of much debate," he said.

This study suggests that the addition of C-reactive protein or fibrinogen to traditional risk factors does slightly improve risk identification, Fonarow said.

"However, the value of testing appears to be marginal," he said. "It is estimated that it would require screening 400 to 500 intermediate-risk individuals to prevent a single cardiovascular event over a 10-year period."

Moreover, the cost of the test compared to its predictive value may make it cost ineffective, Fonarow said.

"The cost of [C-reactive protein] testing for cardiovascular disease is approximately $60 to $150 depending on which laboratory is used, and this cost may or may not be covered by health plans," he said.

Explore further: Inflammatory biomarkers improve the clinical prediction of mortality in COPD

More information: Full Text (subscription or payment may be required)

Related Stories

Inflammatory biomarkers improve the clinical prediction of mortality in COPD

March 16, 2012
The addition of changes in inflammatory biomarkers to established clinical variables improves the prediction of mortality in patients with chronic obstructive pulmonary disease (COPD), according to a new study.

C-reactive protein levels predict breast cancer survival rates

June 3, 2011
Levels of C-reactive protein (CRP) are increased in response to acute inflammation, infection and tissue damage. There are also reports that CRP levels are elevated because of cancer. New research published in BioMed Central's ...

Recommended for you

Laser device placed on the heart identifies insufficient oxygenation better than other measures

September 20, 2017
A new device can assess in real time whether the body's tissues are receiving enough oxygen and, placed on the heart, can predict cardiac arrest in critically ill heart patients, report researchers at Boston Children's Hospital ...

Metabolism switch signals end for healing hearts

September 19, 2017
Researchers have identified the process that shuts down the human heart's ability to heal itself, and are now searching for a drug to reverse it.

Beta blockers not needed after heart attack if other medications taken

September 18, 2017
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge ...

Which single behavior best prevents high blood pressure?

September 15, 2017
(HealthDay)—You probably already know that certain healthy lifestyle behaviors can reduce your risk of developing high blood pressure, but is any one behavior more important than the others?

RESPECT trial shows closing a small hole in heart may protect against recurrent stroke

September 13, 2017
A device used to close a small hole in the heart may benefit certain stroke patients by providing an extra layer of protection for those facing years of ongoing stroke risk, according to the results of a large clinical trial ...

Study shows so-called 'healthy obesity' is harmful to cardiovascular health

September 11, 2017
Clinicians are being warned not to ignore the increased cardiovascular health risks of those who are classed as either 'healthy obese' or deemed to be 'normal weight' but have metabolic abnormalities such as diabetes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.